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Introduction: The epidermal growth factor receptor (EGFR) and its
downstream effector kinases are thought to have important roles in
lung cancer cell proliferation and response to treatment.
Methods: In a prospective cohort of patients with locally advanced
non-small cell lung cancer (NSCLC) undergoing high-dose radio-
therapy with or without chemotherapy, we examined by immuno-
histochemistry (IHC) the tumor levels of EGFR and phosphorylated/
activated-EGFR (P-EGFR), P-Erk, P-Akt, P-Stat3, and the cell cycle
marker Ki67. We examined the relationships among marker expres-
sion, at the plasma membrane (M), cytoplasm (C) and nucleus, as
well as the radiologic tumor response, and overall survival (OS).
Results: Fifty patients were recruited in this study. Their median
survival was 18.3 months. No correlation was detected between total
EGFR and P-EGFR levels in any subcellular compartment. M
P-EGFR correlated positively with C P-Akt (p  0.01). C P-Erk
correlated negatively with radiologic response (p  0.022), and on
univariate regression analysis, this approached significance (p 
0.059). M and C P-EGFR correlated negatively with OS (p 
0.020), and on univariate analysis higher M P-EGFR predicted for
poor OS (p  0.001). Patients with high M P-EGFR levels had
median survival of 7.8 months versus 17.7 months for patients with
low M P-EGFR.
Conclusions: Our results support a role of activated M P-EGFR,
(but not total EGFR), as a predictor of OS in locally advanced-
NSCLC. It is suggested that detailed evaluation of the subcellular
distribution and activation state of EGFR and its downstream effec-
tors is required to unravel the predictive value of these markers in
NSCLC.
Key Words: NSCLC, Radiotherapy, Epidermal growth factor re-
ceptor, Prognostic marker, Extracellular signal regulated kinase.
(J Thorac Oncol. 2008;3: 716–722)
Non-small cell lung cancers (NSCLC) account for 70 to80% of all bronchogenic carcinomas, and the majority
of patients present with locally advanced (LA), unresectable
disease. LA-NSCLC has a poor prognosis with 2-year sur-
vival of 20 to 30% and only 15 to 20% of patients show local
control with curative chemo-radiation therapy (CRT).1 There
is a need to better understand the molecular mechanisms that
regulate malignant growth and resistance to cancer therapies
in NSCLC and to identify biomarkers that are prognostic or
have the power to predict treatment response.
Epidermal growth factor receptor (EGFR) is a trans-
membrane receptor tyrosine kinase that belongs to the ErbB
family consisting of 4 members (ErbB-1/EGFR, c-erbB-2/
Her2, c-erbB3/HER3, and c-erbB4/HER4).2 Binding of the
ligand to EGFR induces receptor dimerization, cross phos-
phorylation of the receptor’s intracellular domain, and acti-
vation of its tyrosine kinase activity. Adaptor molecules are
then recruited to the receptor leading to activation of guanine
nucleotide exchange factors and activation of the small GTP
binding protein Ras, which acts as a master-switch leading to
intracellular effector activation. This results in the activation
of multiple downstream protein and lipid kinase pathways
leading to cell proliferation, survival and resistance to cancer
therapies.2 Such pathways include the Raf/Mitogen Activated
Protein kinase kinase (Mek)/Erk pathway, which has an
established role in cancer cell proliferation,3 and the phos-
phatidylinositol 3-kinase (PI3k)/Akt pathway which, when
activated, is known to lead to cell survival and resistance to
radiotherapy and chemotherapy.4 The signal transducers and
activators of transcription are another family of protein ki-
nases activated by EGFR, and STAT3 is their most prominent
member found activated in NSCLC cells.5,6
In both normal and cancer cells well-orchestrated in-
tracellular membrane traffic and cytoskeletal events facilitate
signal propagation. They guide signaling molecules from
their site of activation in the vicinity of plasma membrane
(M) to specific sites of action in the cytoplasm (C) or the
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nucleus (N)7 to affect metabolic events and gene expression,
respectively.8 This spatial redistribution of signaling mole-
cules is necessary in signal transduction of tyrosine kinase
receptors.9 Although well established in the tumor biology
field, the clinical importance of the subcellular distribution of
EGFR and its effectors has not been elucidated.
To date, a large number of studies have described EGFR
expression in lung cancer, and a few have demonstrated gene
amplification.10 However, repeated efforts to link tumor EGFR
expression to treatment response or overall patient survival have
failed.11,12 It has been suggested that EGFR mutation status and
gene copy number may be better predictors of response to EGFR
inhibitors rather than EGFR levels.13,14
To date, few studies have (1) been prospective in design;
(2) examined the levels of phosphorylated/activated-EGFR
(P-EGFR); (3) examined the specific subcellular distribution of
EGFR and its downstream effectors Erk, Akt, or Stat3; or (4)
examined the relationships of their expression levels with re-
sponses to radiotherapy with or without chemotherapy. For these
reasons, we pursued this prospective cohort study to examine the
association of EGFR, P-EGFR and P-Erk, P-Akt, and P-Stat3
levels with treatment response and overall survival (OS) in
LA-NSCLC patients undergoing treatment with high dose ra-
diotherapy with or without chemotherapy.
PATIENTS AND METHODS
Patient Population
In the period of March 2003 to August 2006, patients
with a diagnosis LA-NSCLC were accrued from the Juravin-
ski Cancer Center at Hamilton Health Sciences in Hamilton,
Ontario, Canada. The protocol and patient consent were
approved by the local research ethics board. All patients
signed consent for the release of archival tumor biopsy tissues
and for the ongoing review of survival and radiologic data.
Eligibility criteria included (1) histologically documented LA-
squamous cell-, poorly differentiated- or adeno-carcinoma (stage
IIB–IIIB as per American Joint Committee on Cancer); (2)
eligible to receive high dose radiotherapy (of 60 Gy) with or
without concurrent or sequential chemotherapy; and (3) ade-
quate core-needle or excisional biopsy tissue available to pursue
immunohistochemistry (IHC) studies.
Radiologic Response and Survival Evaluations
Patients were subjected to computed tomography (CT)-
scans 6 to 8 weeks after treatment and remaining tumor sizes
were compared with those measured on CT-scans obtained
for radiotherapy planning (performed 1–2 weeks before ini-
tiation of radiotherapy). Radiologic response (RR) was de-
termined as the percent of change (1–100) in the sum of the
largest single axis measurements of up to 3 lesions within the
radiation treatment fields (primary plus up to 2 clinically
involved lymph nodes (of 1 cm) when present). This value
demonstrated the percent radiologic tumor volume reduction
or response to curative therapy. All evaluations of CT-scan
images were performed by the investigators (T.T. and J.W.)
blinded from the results of the IHC quantitation (performed
by J-C.C.) or the patients’ survival data (collected by the
clinical trials department, at Juravinski Cancer Center).
Immunohistochemistry
Materials
Commercial monoclonal mouse anti-EGFR antibody
(clone 31G7) was purchased from Zymed Labs (San Francisco,
CA). All phospho-specific rabbit polyclonal antibodies, anti-P-
EGFR, anti-P-p44/42 MAPK (P-Erk) (Thr202/Tyr204), anti-P-
Akt and the anti-P-Stat3) were obtained from Cell Signaling
Technology Inc., (Beverly, MA). The anti-Ki67 antibody (clone
Mib-1) was purchased from Dako Cytomation, (Carpinteria,
CA). Secondary antibodies were purchased from Zymed Labs
(San Francisco, CA). The DAKO EnVision System kit for the
detection of HRP/antibody-antigen reaction was purchased from
DAKO Corporation (Carpinteria, CA).
Technique
Formalin fixed, paraffin embedded tissue sections from
patient tumors and surrounding normal lung were investi-
gated by IHC using the following antibodies dilutions anti-
T-EGFR (1/200), -P-EGFR (1/400), -P-Erk (1/100), -P-Akt
(1/50), -P-Stat3 (1/600), and -Ki67 (1/1000). All IHC was
performed by an experienced clinical technologist. Three-
micrometer-thick cryosections were mounted onto slides and
were deparaffinized in xylene, fixed in pure alcohol, and
endogenous peroxidase was blocked using 3% hydrogen
peroxide. Antigen retrieval was achieved by preheating and
steaming in appropriate buffer, for 20 and 30 minutes, re-
spectively. Nonspecific antigens were blocked with 5% goat
serum and primary antibodies were incubated overnight.
Sections were then incubated with Vector biotinylated appro-
priate secondary antibody (1:500) for 30 minutes followed by
30-minute incubation with Vector ABC reagent. Diamino-
benzidine substrate was added for 10 minutes followed by
wash, dehydration, and mounting.
Immunostaining Quantitation
All samples were assessed for immunoreactivity within
the N, C, and M compartments using a semiquantitative
technique and quantitated by a dedicated lung cancer pathol-
ogist (J-C.C.). Tumor morphology was first reviewed on
H&E stained sections. Diaminobenzidine staining within
each compartment was then systematically scored according
to intensity (0: negative, 1: weak, 2: moderate, 3: strong) and
approximate fraction of cells stained at each given intensity
(0–100) to give a minimum and maximum IHC score of 0 to
300, respectively. In this way, a more specific evaluation of
IHC staining could be achieved, whereby staining at a given
intensity could be given more or less weight according to the
proportion of cells positive at each intensity level.
Statistical Analysis
For correlation analysis we used continuous values of
marker staining. (0–300) Individual scores for each marker,
in each subcellular compartment were compared with scores
of other markers, OS and RR data. For Kaplan-Meyer sur-
vival analysis cases were stratified in 2 categories of Low
Levels (0–100) versus High Levels (101–300) of staining.
Univariate regression analysis was performed to detect the
association of each marker with OS. Multivariate regression
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analysis was performed to identify the best model and the
time-dependent variables were set to assess the proportional
hazards (PH) assumption. If the p value for time-dependent
covariate was less than 0.05, extended Cox PH model was used
to replace the original Cox model. To detect the relationship
between RR values with each marker, the linear regression
model was applied. In addition, a robust linear regression model
with MM estimate (an estimate introduced by Yohai, 1987) was
used to optimize the relationship. A p value 0.05 was consid-
ered statistically significant.
Survival analysis, for the patients with IHC data, was
used to assess the relationship between marker levels, RR and
OS. Kaplan-Meyer method and Log Rank test were used for
descriptive and comparative statistics, respectively. The Cox
PH model was applied to investigate the significance of the
detected relationship between markers and OS.
No corrections for multiple testing of markers and
endpoints was undertaken in this study. The software for
statistical analysis was SAS 9.1.
RESULTS
Patient Population
Fifty consecutive patients with LA-NSCLC eligible for
curative high dose radiotherapy were recruited to this study.
The median follow up period was 26.7 months. The charac-
teristics of the patient population are described in Table 1. All
50 patients completed a course of high dose thoracic radio-
therapy (60–61 Gy, in 30–33 fractions, 180–200 cGy per
fraction) using conformal 3 to 4 field techniques. Forty one
patients (81%) received chemotherapy. Forty-four patients
(88%) had tumor specimens evaluable by IHC.
Survival and Radiologic Response
Curative radiotherapy with or without chemotherapy
resulted in an average 50.2  15.0% reduction (RR) in tumor
volume. Ninety two percent of the patients showed partial
response and 8% stable disease according to standard defini-
tions of disease assessment as per the Response Evaluation
Criteria in Solid Tumors criteria (see Table 1). The median
survival for all patients was 18.32 months.
Immunohistochemistry Results
All antibodies used in this study demonstrated specific
antigen recognition tested both by IHC and by immunoblot-
ting (results not shown). We observed significant staining of
most tumor sections with all markers. Figure 1 illustrates IHC
images for all markers in a representative case of squamous
cell carcinoma. Figure 2A illustrates the IHC scores of the
EGFR pathway markers in the three subcellular compart-
ments of M, C and N. Marker Mean values are shown in a
graph and Mean  SE in a table format. Figure 2B shows the
detected statistically significant correlations among all quan-
titated markers (B).
TABLE 1. Patient Characteristics and Treatment
Age (Mean  SD) 60.0  10.2 (yrs)
Gender No. Patients %
Males 27 54%
Females 23 46%
TNM Stage
IIB 4 8%
IIIA 23 46%
IIIB 23 46%
Histology
Adenocarcinoma 16 32%
Squamous cell carcinoma 15 30%
Poorly differ. carcinoma 19 38%
Chemotherapy
Cisplatin/Etoposide 38 76%
Carboplatin/Gemcitabine 1 2%
Cisplatin alone 1 2%
Cisplatin/Vinorelbine 1 2%
None 9 18%
Results
Median survival 18.3 (mo)
Average radiologic 50.1  15.0%
Response (RR) (Mean  SD)
RECIST
Complete response 0 0%
Partial response 46 92%
Stable disease 4 8%
Progressive disease 0 0%
FIGURE 1. Representative immunohistochemistry (IHC) im-
ages for EGFR, P-EGFR, P-AKT, P-ERK, P-STAT3 and Ki67 in a
case of squamous cell carcinoma. No hematoxylin counter
stain was used for most antibodies to better quantitate Dia-
minobenzidine staining relative to background. Use of
counter stain for Ki67 IHC was necessary to calculate the
fraction of positive tumor nuclei.
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The IHC staining for both total EGFR and P-EGFR was
highest at the M, lower in the C, and undetectable in N.
Staining for P-EGFR was clearly lower than EGFR in all
compartments. Almost undetectable levels of P-Erk were
associated with M. The average staining for P-Erk in M, C
and N is illustrated in Figure 2A, which also demonstrates the
differences in the average subcellular distribution between
P-Erk and EGFR and P-EGFR and the other markers. Low
P-Akt staining was detected at M with approximately equal
average distribution at the C and the N (Figure 2). M levels
of P-Stat3 were also low but unlike P-Akt on average the
majority of P-Stat3 was distributed in the N with a much lower
component of it in C. All tumors examined showed N staining
for Ki67 in the range of 0 to 100 (not shown in figure).
Relationship of EGFR with Its Effector Kinases
We attempted to determine the relationship between
EGFR and P-EGFR, their subcellular distribution and that of
FIGURE 2. A, Immunohistochemistry (IHC) scores of expression of EGFR pathway markers in plasma membrane (M), cyto-
plasma (C) and nucleus (N) are shown both in a 3D graphic (Means) and table format (Mean  SE). B, All detected statisti-
cally significant correlations between markers with p  0.1 are shown.
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its downstream effector kinases. Figure 2B shows all poten-
tial correlations between these parameters with p  0.1.
There was a significant positive correlation between M EGFR
and C EGFR and between M P-EGFR and C P-EGFR, but
interestingly there was no correlation between the EGFR
levels and those of P-EGFR, in any of the subcellular com-
partments. We did not detect any significant correlation
between EGFR or P-EGFR and the levels of P-Erk. A
significant positive correlation was detected between M
P-EGFR and the C levels of P-Akt. Finally, we detected a
significant positive correlation between C P-EGFR (not
total EGFR) and the level of Ki67 staining of these tumors
(R  0.74, p  0.008, see Figure 2B).
Relationship of Markers with Tumor
Radiologic Response
We analyzed the marker relationships with RR by
correlation and by regression analysis. Of all examined mark-
ers only C P-Erk showed a significant correlation with RR
(p  0.02). This was a negative correlation indicating that
higher levels of C P-Erk are associated with a poor RR of
these tumors to CRT. On univariate regression analysis C
P-Erk showed a trend to associate with RR also in a negative
manner (p  0.059). Figure 3 illustrates this relationship. No
other marker showed a considerable relationship with RR in
this study including Ki67.
Relationship of Markers with OS in Patients
with IHC Data
C levels of EGFR showed a weak negative correlation
with OS, which approached but did not reach statistical
significance (R  0.31, p  0.058). However, P-EGFR in
both M and C showed statistically significant negative cor-
relations with OS as shown (M: R  0.47, p  0.020; C:
R  0.48, p  0.039). Univariate analysis using the Cox
model showed that M P-EGFR is a predictor for poor OS
(p  0.018). For survival analysis we constructed Kaplan-
Meyer curves and plotted survival curves for the patients with
Low Levels (0–100) and High Levels (101–300) M P-EGFR
staining. Figure 4 illustrates the significant difference in
survival in patients with “High” M P-EGFR versus Low M
P-EGFR (hazard ratio  7.77, 95% confidence interval 
2.25–26.85, p  0.001). Using Kaplan-Meyer approach we
estimated the median survival (95% confidence interval) to be
17.7 months (14.3–25.5) for the patients expressing Low
Levels of M P-EGFR versus 7.8 months (5.8–11.4) for those
expressing High Levels of this marker. Apart from P-EGFR
no other marker showed either a trend or a significant asso-
ciation with OS, including Ki67.
DISCUSSION
The present study was designed to evaluate whether
total and activated EGFR and activated downstream effector
kinases Erk, Akt and Stat3 are potential markers of survival
or disease response in LA-NSCLC. According to the biomar-
ker glossary a prognostic biomarker is one that can predict
patient survival independent of the therapeutic modality used,
whereas a predictive biomarker is one that can predict disease
response to one treatment compared with another.15 In con-
formity with these definitions in this study we have examined
the prognostic value of EGFR pathway markers. We have
also examined the association of these markers with the
tumor’s RR to radiotherapy.
It is well understood that the cellular action of EGFR
and its effector kinases is mediated by the activated/phos-
phorylated forms of these enzymes through translocation to C
and the N.3 For this reason we focused here mainly on the
FIGURE 3. Univariate regression
analysis results of radiologic re-
sponse (RR) (response %) versus
Cytoplasmic P-Erk IHC score
(C-P-Erk). p values for regression:
p  0.059 and correlation p  0.022.
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phosphorylated form of these kinases and adjusted our IHC
quantitation technique to better represent the subcellular dis-
tribution of the probed markers. The relationship of the levels
of protein expression and subcellular distribution of these
molecules in their activated form, with tumor RR and patient
OS has not been examined in depth in prospective studies of
LA-NSCLC patients treated with standard protocols of radio-
therapy and chemotherapy.
Marker Relationships
Although we detected strong EGFR staining in M, in
this study, this was not paralleled by equally strong P-EGFR
levels in this compartment (Figure 2). Since we detected
almost equal EGFR and P-EGFR staining in C, this suggests
that only a small proportion of the total receptor may indeed
be activated. Such findings were also detected by Cortas
et al.16 who reported that only 1/3 of total EGFR is activated
in resected NSCLC tumors.
Our finding of M P-EGFR correlating positively with C
P-Akt (Figure 2B) is in agreement with the known role of
EGFR in stimulating antiapoptotic signals through Akt acti-
vation. This is an established action of EGFR and activated
Akt in preclinical models4 and is consistent with our obser-
vation of P-EGFR as a prognostic indicator (predictor) of
poor survival (Figure 4). Akt is suggested to mediate tumor
cell survival and radiation protection.4 However, P-Akt de-
tected by IHC was associated with better response to Ge-
fitinib and longer time to progression in 2 NSCLC stud-
ies.17,18 In bronchoalveolar carcinoma Akt activation did not
have a prognostic significance.19 In agreement with the latter
report we did not observe a statistically significant association
of P-Akt with either RR or OS in the present study.
Erk and Stat3 have been investigated in surgical series
of NSCLC patients16,20 and an association was detected
between P-EGFR and P-Stat3. Here, we did not detect any
significant correlation between EGFR or P-EGFR and either
P-Erk or P-Stat3. The strong correlation of Ki67 with C
P-EGFR detected here (Figure 2B) suggests that higher levels
of C P-EGFR may be implicated in more intense prolifera-
tion-inducing signal transduction to the N and increased
tumor cell cycling. Clarification whether a cause-effect rela-
tionship exists or not between EGFR activation and activation
of downstream effector kinases in vivo, is important in
understanding better lung cancer biology. IHC studies are not
ideal tools for elucidation of molecular interactions but do
offer a unique view of the in vivo tumor milieu. Therefore,
further studies with larger numbers of patients would be
useful.
Marker Relationships with OS and RR
Relationships with RR
The value of radiologic evaluation of in-field tumor
response in lung cancer patients undergoing radiotherapy
remains controversial. We detected a significant negative
correlation of tumor RR with C P-Erk levels on regression
analysis (see Figure 3). The upstream regulator of Erk, Ras,
is implicated in radiation resistance and our results are con-
sistent with a possible role of C P-Erk in resistance to CRT.
Hagan et al. demonstrated activation of Erk by radiation and
enhanced cell killing with Erk inhibition in prostate cancer
cells.21 In addition, in NSCLC Vicent et al. 20 observed that
patients with increase C P-Erk demonstrated poorer survival
but this did not reach significance in multivariate analysis.
FIGURE 4. Kaplan-Meyer survival
analysis: Survival Time (months) for
patients with high levels (101–300)
versus low levels (0–100) immuno-
histochemistry scores of plasma
membrane P-EGFR expression (M
P-EGFR). Univariate Cox model anal-
ysis: hazard ratio: 7.77, 95% confi-
dence interval: 2.2 to 26.8,
p  0.001. Median survival (95%
confidence interval) for patients
with low levels of M P-EGFR: 17.7
months (14.3–25.5) and high levels
of M P-EGFR: 7.8 months
(5.8–11.4).
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Relationships with OS
The majority of the literature in NSCLC has investi-
gated the prognostic and predictive role of total EGFR levels.
Two meta-analyses attempted to elucidate the relationship of
EGFR expression with OS.11,12 Meert et al.,11 analyzed stud-
ies performed in the 1990s of different methods of EGFR
evaluation and found that overall EGFR expression was not a
prognostic factor for survival, except in a subset of studies
where IHC was used and there the impact was small as a
prognostic factor for survival. Furthermore, in a recent meta-
analysis Nakamura et al.12 found that EGFR expression was
not associated with poor survival.
Other studies could not demonstrate an association
between P-EGFR and OS in early stage resected NSCLC
tumors.16 However, here both M and C P-EGFR showed
statistically significant negative correlation with OS indicat-
ing that P-EGFR may have prognostic value in LA-NSCLC
patients treated with CRT. This was supported for M P-EGFR
by univariate analysis using Cox model (p  0.018). The
results of Figure 4 show that high levels of M P-EGFR
predicts poor OS in patients with LA-NSCLC treated with
curative CRT.
The present study was a prospective single institution
protocol pursued mainly for hypothesis generation. The small
number of patients may have been a limitation in this study in
terms of demonstrating stronger statistical findings. Never-
theless, this study was still able to demonstrate the value of
activated EGFR (P-EGFR) as prognostic biomarker in LA-
NSCLC indicating its biologic importance. It is possible that
the antibodies and the detection kits used in the present study
may have permitted detection of IHC differences that were
not seen in other studies. We aim to verify our results within
a larger prospective cohort and within randomized clinical
trials with LA-NSCLC patients.
CONCLUSIONS
In conclusion, this study examined in a prospective
manner the value of activated EGFR and its downstream
effector kinases (Erk, Akt and Stat3) as biomarkers in a
cohort of patients with LA-NSCLC undergoing high dose
radiotherapy with or without chemotherapy. We observed
that high M P-EGFR levels, but not total EGFR, predict poor
OS. C P-Erk correlated with poor tumor RR response in this
patient population. Also, we found that (1) total EGFR levels
do not reflect the extent of EGFR activation (P-EGFR); (2) M
P-EGFR correlates with C P-Akt; and (3) C P-EGFR cor-
relates strongly with Ki67. These results suggest that M
P-EGFR has a strong potential to develop as a prognostic
biomarker in LA-NSCLC. To unravel the true value of EGFR
pathway signaling molecules as biomarkers in NSCLC, their
activation state and subcellular distribution should be inves-
tigated within large prospective clinical trials.
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